

## Pacmilimab

Cat. No.:	HY-P99799
CAS No.:	2145091-51-4
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity <sup>[1]</sup> .
In Vivo	Pacmilimab induces antitumor responses comparable to those of the same dose of the parental antibody in mice bearing MC38 tumors <sup>[1]</sup> . Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Naing A, et al. CX-072 (pacmilimab), a Probody<sup>®</sup> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. *J Immunother Cancer*. 2021 Jul;9(7):e002447.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA